20 Stocks That Could Double Your Money in 2020
Big gains could be just a click of the buy button away.
Aimmune Therapeutics
AIMT
AIMT
$29.65
$0.52
1.8%
BATS BZX Real Time Price as of December 6, 2019, 4:00 p.m. EST
View Interactive AIMT Charts
Aimmune Therapeutics, Inc.
News & Analysis: Aimmune Therapeutics
Aimmune Therapeutics Inc (AIMT) Q3 2019 Earnings Call Transcript
AIMT earnings call for the period ending September 30, 2019.
Here's Why Aimmune Therapeutics Stock Jumped on Wednesday
A survey of allergists suggests Palforzia's launch could be more successful than expected.
Will Vaping Deaths Derail Marijuana Stocks? Plus, a New Treatment for Peanut Allergies Advances
How vaping risks may impact cannabis companies and Aimmune Therapeutics' plan to change how doctors treat peanut allergies.
Did the FDA Just Signal Smooth Sailing Ahead For Aimmune Therapeutics?
Here's what a benign briefing document means, and what it doesn't.
Here's Why Aimmune Therapeutics Stock Is Surging Today
The company's peanut allergen desensitization therapy took an indirect step forward.
3 Biotech Stocks That Could Soar This Week
Investors better get ready for a busy week ahead.
3 Top Biotech Stocks to Buy in August
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Call Transcript
AIMT earnings call for the period ending June 30, 2019.
Here's Why Aimmune Therapeutics Fell 7% Today
The Institute for Clinical and Economic Review questions the short-term risks of the biotech's drug.
